Autobahn’s elunetirom Fast Track win puts bipolar depression back in regulatory focus
Bipolar depression needs better options. Autobahn’s elunetirom Fast Track status raises the stakes for its Phase 2 readout.
Pharma & Biotech
Medical Devices & Diagnostics
Why Hologic’s Breast Cancer Index data matter for precision oncology beyond recurrence risk
Hologic’s Breast Cancer Index is changing endocrine therapy decisions. The bigger test is adoption in real-world breast cancer care.
Medical Devices & Diagnostics
Why DePuy Synthes’ Gemtrack deal could reshape navigation in hip, knee and shoulder surgery
DePuy Synthes wants to remove a robotics bottleneck. Its Gemtrack deal could change joint surgery navigation if regulators agree.
Pharma & Biotech
Why LIB Therapeutics’ lerodalcibep data matter for next-generation cholesterol care
Monthly PCSK9 therapy is getting crowded. LIB Therapeutics’ LEROCHOL data raise a sharper question on adherence, access and durability.
Pharma & Biotech
Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?
Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.
Pharma & Biotech
Is Arrowhead’s plozasiran becoming the RNAi drug to watch in extreme triglyceride disorders?
Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.
Pharma & Biotech
Emalex Biosciences advances Tourette syndrome strategy as ecopipam delays relapse in Phase 3 trial
D1 receptor targeting may change Tourette syndrome care. Ecopipam’s Phase 3 data now face the bigger test: regulation and adoption.
Pharma & Biotech
Marea Therapeutics targets acromegaly treatment burden with long-acting MAR002 antibody
Daily acromegaly injections face a convenience challenge. Marea’s MAR002 could reset expectations if Phase 1 durability translates.
Pharma & Biotech
Acurex Biosciences moves 15-lipoxygenase program closer to Parkinson’s disease clinical testing
Parkinson’s drugs still treat symptoms. Acurex’s ASAP grant puts 15-lipoxygenase and ferroptosis into sharper disease-modifying focus.
Pharma & Biotech
How RenovoRx’s TAMP platform data could reshape intra-arterial drug delivery in pancreatic cancer
RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.